



(12) Translation of
European patent specification

(11) NO/EP 3144318 B1

NORWAY

(19) NO
(51) Int Cl.
A61P 15/00 (2006.01)
A61K 38/00 (2006.01)
A61P 15/08 (2006.01)
C07K 14/59 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.02.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.09.23
(86)	European Application Nr.	16194925.0
(86)	European Filing Date	2009.04.16
(87)	The European Application's Publication Date	2017.03.22
(30)	Priority	2008.04.25, EP, 08251528 2008.04.16, US, 45424 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(73)	Proprietor	Ferring B.V., Polaris Avenue 144, 2132 JX Hoofddorp, Nederland
(72)	Inventor	COTTINGHAM, Ian, Ferring International Center S.A.Ch. de la Vergognausaz 50, 1162 Saint-Prex, Sveits PLAKSIN, Daniel, Ferring International Center S.A.Ch. de la Vergognausaz 50, 1162 Saint-Prex, Sveits WHITE, Richard Boyd, -, deceased, USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	RECOMBINANT FSH INCLUDING ALPHA 2,3- AND ALPHA 2,6-SIALYLATION
(56)	References Cited:	WO-A-03/035686 WO-A1-2012/016576 FLACK M R ET AL: "Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM SEP 1994, vol. 79, no. 3, September 1994 (1994-09), pages 756-760, XP002494715, ISSN: 0021-972X DICKY RICHARD P ET AL: "Highly purified human-derived follicle-stimulating hormone (Bravelle(R)) has equivalent efficacy to follitropin-beta (Follistim (R)) in infertile women undergoing in vitro fertilization", REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, BIOMED CENTRAL LTD, GB, vol. 1, no. 1, 63, 3 October 2003 (2003-10-03), pages 1-8, XP021009333, ISSN: 1477-7827, DOI: 10.1186/1477-7827-1-63

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Rekombinant FSH (rFSH), som inkluderer α 2,3- og α 2,6-sialylering, hvor fra 10% til
5 20% av den totale sialyleringen er α 2,6-sialylering.

2. En farmasøytisk sammensetning, som omfatter rekombinant FSH ifølge krav 1.

3. En farmasøytisk sammensetning ifølge krav 2, som videre omfatter hCG og/eller LH.
10

4. En farmasøytisk sammensetning ifølge krav 2 eller krav 3, for bruk i behandlingen av infertilitet.